Top-Rated StocksTop-RatedNASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $29.65 +0.13 (+0.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$29.23▼$30.2450-Day Range$23.90▼$35.9552-Week Range$13.57▼$53.08Volume392,068 shsAverage Volume774,355 shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$61.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arvinas alerts: Email Address Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside106.2% Upside$61.13 Price TargetShort InterestBearish15.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.08) to ($4.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector798th out of 936 stocksPharmaceutical Preparations Industry372nd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has only been the subject of 4 research reports in the past 90 days.Read more about Arvinas' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.55% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently increased by 11.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.6 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arvinas this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows3 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($4.08) to ($4.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesJuly 26 at 4:34 PM | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)July 19, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Shares Gap Up to $32.73July 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 18, 2024 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Sees Large Increase in Short InterestJuly 12, 2024 | seekingalpha.comArvinas: Hugely Important Data Catalyst Upcoming - Success May Prove ElusiveJune 24, 2024 | globenewswire.comArvinas Appoints Andrew Saik as Chief Financial Officer and TreasurerJune 21, 2024 | globenewswire.comArvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2June 17, 2024 | globenewswire.comArvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.July 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 3, 2024 | globenewswire.comArvinas to Participate in Upcoming Investor ConferencesMay 23, 2024 | globenewswire.comArvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual CongressMay 23, 2024 | finance.yahoo.comIt Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The MicroscopeMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Holding Company on Strong Clinical Trial Results and Competitive Market PositioningMay 17, 2024 | markets.businessinsider.comBuy Rating on Arvinas for Promising Breast Cancer Therapy and Market PotentialMay 16, 2024 | markets.businessinsider.comArvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+PalbociclibMay 16, 2024 | globenewswire.comArvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)May 11, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Arvinas with Promising Trial Updates and Robust Financial OutlookSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees420Year FoundedN/APrice Target and Rating Average Stock Price Target$61.13 High Stock Price Target$90.00 Low Stock Price Target$20.00 Potential Upside/Downside+106.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net MarginsN/A Pretax Margin-493.69% Return on Equity-64.79% Return on Assets-30.46% Debt Debt-to-Equity RatioN/A Current Ratio4.94 Quick Ratio4.94 Sales & Book Value Annual Sales$78.50 million Price / Sales25.85 Cash FlowN/A Price / Cash FlowN/A Book Value$11.99 per share Price / Book2.47Miscellaneous Outstanding Shares68,430,000Free Float64,853,000Market Cap$2.03 billion OptionableOptionable Beta1.98 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 64)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 61)Chief Scientific Officer Comp: $692kDr. Randy Teel Ph.D. (Age 44)Interim CFO & Treasurer Mr. David K. Loomis M.B.A. (Age 50)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsMr. Jared M. Freedberg J.D. (Age 55)General Counsel & Corporate Secretary Mr. Steve Weiss (Age 54)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 67)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 56)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 46)Chief Commercial Officer More ExecutivesKey CompetitorsPliant TherapeuticsNASDAQ:PLRXAnnexonNASDAQ:ANNXEnanta PharmaceuticalsNASDAQ:ENTADyne TherapeuticsNASDAQ:DYNSummit TherapeuticsNASDAQ:SMMTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 57,835 shares on 7/26/2024Ownership: 0.344%Allspring Global Investments Holdings LLCBought 1,728 shares on 7/26/2024Ownership: 0.021%Banque Pictet & Cie SASold 2,551 shares on 7/25/2024Ownership: 0.120%Hennion & Walsh Asset Management Inc.Bought 4,045 shares on 7/20/2024Ownership: 0.096%SG Americas Securities LLCBought 49,799 shares on 7/12/2024Ownership: 0.126%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $41.16 at the beginning of the year. Since then, ARVN stock has decreased by 28.0% and is now trading at $29.65. View the best growth stocks for 2024 here. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.97) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.45. The company's revenue was down 22.2% on a year-over-year basis. When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Top institutional shareholders of Arvinas include Bank of New York Mellon Corp (0.34%), SG Americas Securities LLC (0.13%), Banque Pictet & Cie SA (0.12%) and Hennion & Walsh Asset Management Inc. (0.10%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Ronald Peck, Bradley Albert Margus, Briggs Morrison, Liam Ratcliffe and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK) and Advanced Micro Devices (AMD). This page (NASDAQ:ARVN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
